CAR T-cell therapy has revolutionized cancer treatment, offering hope to patients with multiple myeloma. But here's the shocking truth: this groundbreaking therapy can trigger severe, delayed side effects, including neurotoxicity and intestinal inflammation, which have been linked to a startling number of non-cancer-related deaths, primarily from infections. And this is the part most people miss: these life-threatening complications, known as CAR T–associated immune-related adverse events (CirAE), share a common root cause tied to the CCR5 pathway. This revelation, presented at the American Society of Hematology Annual Meeting, could transform how we manage these risks and save lives.
Researchers at the University of Pennsylvania uncovered this connection through a meticulous investigation. They found that CirAE, which emerge weeks or months after B-cell maturation antigen–directed (BCMA) CAR T-cell therapy, differ from the well-known immediate toxicities like cytokine release syndrome. Instead, these delayed effects include cranial nerve palsies, Parkinsonism, optic neuritis, encephalopathy, enterocolitis, and arthritis. Strikingly, patients treated with ciltacabtagene autoleucel (cilta-cel) experienced CirAE at a rate of 20%, compared to just 2.7% in those receiving idecabtagene vicleucel (ide-cel), with ide-cel cases primarily involving pneumonitis.
But here's where it gets controversial: the UPenn team identified a shared immunologic driver behind these diverse symptoms—the overexpansion and tissue trafficking of CD4+ CAR T cells. This finding challenges the notion that these side effects are unrelated, opening the door to targeted interventions. For instance, patients with high absolute lymphocyte counts (ALC) or elevated CD4:CD8 ratios shortly after infusion are now flagged as high-risk and treated with dexamethasone to curb CD4+ CAR T expansion. However, this steroid-based approach may not be sustainable long-term, as it increases infection risks.
What if there’s a better way? The researchers pinpointed a specific mechanism: an IL-15–driven CCL5–CCR5 loop that fuels CD4-dominant CAR T expansion. Blocking CCR5 with maraviroc, an HIV medication, or using CCR5-knockout CAR T cells, suppressed expansion while maintaining the therapy’s cancer-killing power. This non-steroid approach could revolutionize CirAE management, but it raises a critical question: Can we safely modulate CAR T-cell behavior without compromising efficacy or patient safety?
Penn Medicine has already updated its guidelines, but the journey doesn’t end here. The team plans to explore both steroidal and CCR5 inhibition strategies post-infusion and investigate modifying T-cell manufacturing to optimize CD4:CD8 ratios. As BCMA CAR T therapy moves into earlier treatment stages, these findings will be crucial for refining patient selection and risk-stratified monitoring.
Here’s the burning question for you: With the potential to prevent CirAE using CCR5-directed strategies, should we prioritize this approach over traditional steroid treatments, even if it means navigating uncharted territory? Share your thoughts in the comments—let’s spark a conversation that could shape the future of CAR T therapy.
